T2 Biosystems, Inc.

Equities

TTOO

US89853L3024

Advanced Medical Equipment & Technology

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-18 pm EDT			5-day change	1st Jan Change
2.99 ^USD	+1.70%		-5.08%	-52.35%

Apr. 01	T2 Biosystems, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
Mar. 28	T2 Biosystems Announces Extension of Multi-Year Capital Equipment Supplier Agreement with Vizient, Inc	CI

T2 Biosystems to Participate in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum

November 09, 2022 at 04:07 pm EST

LEXINGTON, Mass., Nov. 09, 2022 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced plans to participate in the upcoming Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum in New York, New York.

Management is scheduled to present on Thursday, November 17, 2022, at 2pm ET. Interested parties may access a live and recorded webcast of the presentation on the “Investors” section of the Company’s website at www.t2biosystems.com.

About T2 Biosystems
T2 Biosystems, a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, is dedicated to improving patient care and reducing the cost of care by helping clinicians effectively treat patients faster than ever before. T2 Biosystems’ products include the T2Dx^® Instrument, the T2Bacteria^® Panel, the T2Candida^® Panel, the T2Resistance^® Panel, and the T2SARS-CoV-2™ Panel and are powered by the proprietary T2 Magnetic Resonance (T2MR^®) technology. T2 Biosystems has an active pipeline of future products, including the T2Biothreat™ Panel, the T2Cauris™ Panel, and T2Lyme™ Panel, as well as next-generation products for the detection of bacterial and fungal pathogens and associated antimicrobial resistance markers.

Investor Contact:
Philip Trip Taylor, Gilmartin Group
philip@gilmartinIR.com
415-937-5406

Source: T2 Biosystems, Inc.

2022 GlobeNewswire, Inc., source Press Releases

Latest news about T2 Biosystems, Inc.

T2 Biosystems, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 01	CI
T2 Biosystems Announces Extension of Multi-Year Capital Equipment Supplier Agreement with Vizient, Inc	Mar. 28	CI
T2 Biosystems, Inc. Reiterates Revenue Guidance for the Year 2024	Mar. 20	CI
Transcript : T2 Biosystems, Inc. - Special Call	Mar. 20
T2 Biosystems Unveils T2Lyme Launch Plans and Provides Additional Business Updates	Mar. 20	CI
T2 Biosystems, Inc. Announces Publication of New Study Highlighting Clinical Benefits and Performance of Real-World Use of T2Resistance Panel in Journal of Clinical Microbiology	Mar. 18	CI
Transcript : T2 Biosystems, Inc., Q4 2023 Earnings Call, Feb 15, 2024	Feb. 15
T2 Biosystems, Inc. Announces Commercial Expansion Through Distributors in Europe and Asia	Feb. 15	CI
Sector Update: Health Care Stocks Mixed Late Afternoon	Feb. 12	MT
Sector Update: Health Care Stocks Steady in Afternoon Trading	Feb. 12	MT
T2 Biosystems Gets FDA Clearance for Expanded T2Bacteria Panel; Shares Rise	Feb. 12	MT
T2 Biosystems Gets 510(k) Clearance For Expanded T2Bacteria Panel	Feb. 12	DJ
T2 Biosystems Receives FDA 510(k) Clearance for the Expanded T2Bacteria Panel	Feb. 12	CI
T2 Biosystems Announces Participation in NIH-Funded Antibacterial Resistance Leadership Group Pilot Study for Pneumonia Patients	Jan. 18	CI
T2 Biosystems, Inc. Announces the Resignation of Thierry Bernard as Class II Director and All Committees of the Board of Directors	Jan. 05	CI
T2 Biosystems, Inc. Announces FDA 510(K) Submission to Expand Use of the FDA-Cleared T2candida Panel to Include Pediatric Testing	Jan. 03	CI
T2 Biosystems, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 15	CI
T2 Biosystems, Inc. Highlights New Clinical Data Presented At IDWeek 2023 Conference	23-10-24	CI
T2 Biosystems, Inc. Announces Amendment and Extension of CRG Term Loan Agreement	23-10-23	CI
T2 Biosystems Submits 510(k) to Add Detection of Acinetobacter Baumannii to List of Pathogens Covered by T2Bacteria Panel	23-10-12	MT
Transcript : T2 Biosystems, Inc., Q3 2023 Earnings Call, Oct 12, 2023	23-10-12
Sector Update: Health Care Stocks Decline in Late Afternoon	23-10-12	MT
Top Midday Decliners	23-10-12	MT
Sector Update: Health Care Stocks Lower Thursday Afternoon	23-10-12	MT
T2 Biosystems Announces 1-for-100 Reverse Stock Split; Shares Fall	23-10-12	MT

Chart T2 Biosystems, Inc.

Duration

Period

More charts

Company Profile

T2 Biosystems, Inc. is an in vitro diagnostics company focused on the detection of sepsis-causing pathogens and antibiotic resistance genes. Its technology enables detection of pathogens, biomarkers and other abnormalities in a variety of unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum and urine, and can detect cellular targets at limits of detection as low as one colony forming unit per milliliter (CFU/mL). Its focus includes three areas: sepsis, bioterrorism, and Lyme disease. The Company's products include the T2Dx Instrument, the T2Bacteria Panel, the T2Candida Panel, the T2Resistance Panel, and the T2Biothreat Panel, and are powered by the T2 Magnetic Resonance (T2MR) technology. It also has an active pipeline of products, including the United States T2Resistance Panel, the Candida auris test, and the T2Lyme Panel. T2Dx Instrument is a fully automated instrument that is capable of running a range of diagnostic tests from patient samples.

Sector

Advanced Medical Equipment & Technology

Calendar

2024-05-01 - Q1 2024 Earnings Release (Projected)

More about the company

	1st Jan change	Capi.
T2 BIOSYSTEMS, INC.	-52.35%	16.48M
THERMO FISHER SCIENTIFIC	+2.02%	207B
DANAHER CORPORATION	+2.17%	175B
INTUITIVE SURGICAL, INC.	+10.45%	132B
BOSTON SCIENTIFIC CORPORATION	+16.62%	99.1B
SIEMENS HEALTHINEERS AG	-3.42%	60.89B
EDWARDS LIFESCIENCES CORPORATION	+13.38%	52.04B
SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.	-6.33%	45.48B
AGILENT TECHNOLOGIES, INC.	-4.74%	38.81B
GE HEALTHCARE TECHNOLOGIES INC.	+9.89%	38.77B

Other Advanced Medical Equipment & Technology

T2 Biosystems, Inc.

Equities

TTOO

US89853L3024

Advanced Medical Equipment & Technology

T2 Biosystems to Participate in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum

Latest news about T2 Biosystems, Inc.

Chart T2 Biosystems, Inc.

Company Profile

Income Statement Evolution

Quarterly earnings - Rate of surprise

Sector Other Advanced Medical Equipment & Technology